Compliance Studio Resource Center

The development of Compliance Studio originated from a recurring observation in regulatory practice. Across more than 200 interviews with Regulatory Affairs and Quality Assurance professionals in medical devices, IVD, pharmaceuticals, and biotechnology, a consistent pattern emerged. The central challenge was not access to regulatory information, nor a lack of tools. Instead, it concerned the ability to determine and maintain a correct regulatory scope for a given product acro

Determining regulatory scope has always been a foundational task in Regulatory Affairs. It concerns which regulations apply to a given product, across which markets, and how that evolves over time. In practice, this has rarely been established as a stable construct. Instead, it is built and maintained through a combination of regulatory interpretation, internal documentation, and accumulated experience. This approach can function operationally. However, it introduces recurrin

Most discussions about the MDR and IVDR transition focus on deadlines, delays, and notified body bottlenecks. But for many manufacturers, the real, lasting effect has emerged elsewhere. The transition has not just changed when  things need to be done—it has changed how  regulatory scope must be defined, structured, and defended. For the first time in years, the question is no longer just whether requirements have been identified, but whether the very structure for managing th

Most regulatory teams believe they have control over their Applicable List. It exists. It gets updated now and then. It has worked so far. But audit exposure rarely arises from obvious omissions—a forgotten regulation, an overlooked standard. It emerges more subtly. It begins when confidence in the list's reliability gradually erodes, without anyone really noticing. As regulatory scope expands—across markets, product variations, and new domains such as cybersecurity and AI—ma